BioSpace News Archive

Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, partners with NTT DATA Singapore to introduce Lunit INSIGHT CXR to Singapore’s public healthcare system.

Naveris, Inc. announced that Palmetto GBA, the Medicare Administrative Contractor that administers the Molecular Diagnostics Services program, established Medicare coverage for NavDx®, Naveris’ proprietary flagship blood test for Tumor Tissue Modified Viral -HPV DNA.

Clarity Pharmaceuticals (ASX: CU6) (“Clarity”) is pleased to announce it has commenced its registrational Phase III 64Cu-SAR-bisPSMA diagnostic trial in prostate cancer, CLARIFY (NCT06056830)[1], with the initiation of the first clinical site at the Urology Cancer Center / XCancer Omaha, NE.

MaaT Pharma announced that its ongoing Phase 2b trial, called Phoebus, aimed at evaluating MaaT033 to improve overall survival for patients receiving allo-HSCT2 has been selected for funding, in response to the ‘Innovation in Biotherapy and Bioproduction’ call for projects from the ‘Biotherapies and Bioproduction of Innovative Therapies’ acceleration strategy, operated by Bpifrance.

CG Oncology, Inc. today announced that Phase 3 monotherapy data from the BOND-003 clinical trial evaluating the efficacy and safety of cretostimogene grenadenorepvec in patients with high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG), showed that 75.7% of evaluable patients achieved a complete response (CR) at any time, as of the cutoff date of October 5, 2023.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will host a conference call and simultaneous webcast to provide an update on the company’s hematology portfolio on Thursday, December 14, 2023 at 8:30 AM ET.

Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by SpringWorks Therapeutics for Ogsiveo™ (nirogacestat).

This week, Aspen Neuroscience will present to the Parkinson’s community at the Future of Parkinson’s Disease conference, held November 30 – December 3, in Austin.

QIAGEN and DNA Labs International announced that DLI has recently solved two decades-old “cold cases” using QIAGEN solutions.

Congruence Therapeutics announced that it will participate in the 2023 RBC Capital Markets Healthcare Private Company Conference, being held in a virtual format December 13-14, 2023.